On Jun 29, 2018 Raymond James Analyzed CymaBay Therapeutics (NASDAQ:CBAY) with $20 Target.

June 29, 2018 - By Daniel Cummings

What Price Target Has Raymond James Given CymaBay Therapeutics (NASDAQ:CBAY)

On 28 June a research report was published on CymaBay Therapeutics (NASDAQ:CBAY) of its “Outperform” Rating maintained by stock analysts at Raymond James. The market cap company coverage has begun with $20 TP that indicates 48.81 % upside potential from the previous close.

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Ratings Coverage

Total analysts of 9 have positions in CymaBay Therapeutics (NASDAQ:CBAY) as follows: 9 rated it a “Buy”, 0 with “Sell” and 0 with “Hold”. The positive are 100%. Since January 10, 2018 according to StockzIntelligence Inc CymaBay Therapeutics has 17 analyst reports. On Wednesday, March 28 the stock of CymaBay Therapeutics, Inc. (NASDAQ:CBAY) has “Buy” rating given by Leerink Swann. The stock rating was maintained by Cantor Fitzgerald with “Buy” on Tuesday, June 26. On Wednesday, January 24 the firm has “Buy” rating by H.C. Wainwright given. On Friday, March 16 the stock of CymaBay Therapeutics, Inc. (NASDAQ:CBAY) earned “Buy” rating by SunTrust. On Wednesday, March 28 the company was initiated by H.C. Wainwright. On Thursday, January 25 the stock of CymaBay Therapeutics, Inc. (NASDAQ:CBAY) earned “Buy” rating by Roth Capital. On Monday, April 16 the firm earned “Buy” rating by Roth Capital. On Wednesday, March 21 the rating was maintained by Oppenheimer with “Buy”. The company rating was maintained by Cantor Fitzgerald on Friday, March 16. The company rating was maintained by Oppenheimer on Wednesday, May 9.

CBAY reached $13.44 during the last trading session after $0.06 change.Currently CymaBay Therapeutics, Inc. is uptrending after 171.12% change in last June 29, 2017. CBAY has 163,460 shares volume. The stock outperformed the S&P 500 by 158.55%.

CymaBay Therapeutics, Inc. (NASDAQ:CBAY)’s earnings release is expected by WallStreet on August, 9, RTT reports. Analysts have expectation on stock’s EPS of $-0.24. That’s up 22.58 % from last year’s $-0.31 EPS. Analysts at Wall Street see CymaBay Therapeutics, Inc.’s -25.00 % EPS growth compared to $-0.32 EPS for previous quarter.

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases.The firm is valued at $789.85 million. The Company’s lead product candidate is seladelpar, a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase II clinical study for the treatment of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis.Currently it has negative earnings. The firm also develops arhalofenate, which has completed five Phase II clinical trials for the treatment of patients with gout; and MBX-2982, an oral G-protein coupled receptor agonist that has completed one Phase II clinical trial for therapeutic indications.

For more CymaBay Therapeutics, Inc. (NASDAQ:CBAY) news announced recently go to: Seekingalpha.com, Seekingalpha.com, Streetinsider.com, Seekingalpha.com or Nasdaq.com. The titles are as follows: “Key events next week – healthcare” announced on June 21, 2018, “Intercept And Obeticholic Acid Therapy: Discerning Scientific Facts From Fallacies On Cholestatic Liver Diseases” on June 12, 2018, “SunTrust Robinson Humphrey Remains Bullish on CymaBay Therapeutics (CBAY) Following Analyst & Investor Day” with a publish date: June 28, 2018, “Reader Inquiry: What’s The Updated Outlook For CymaBay Therapeutics?” and the last “CymaBay Therapeutics Added to the Russell 3000® and Russell 2000® Indexes” with publication date: June 25, 2018.

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.